NASDAQHealth CareBiotechnologySnapshot 2026-07-09
Reading EIKN? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →Warn: Management is running behind on a stated commitment.
Eikon Therapeutics aims to fund operations into the second half of 2027 with $596M cash. Operating losses are managed but increased from -$71.4M to -$87.3M in 2026-Q1. The company advances product development with six abstracts at ASCO 2026.
Operating losses worsened to -$87.3M in 2026-Q1 and net income declined to -$82.9M. The company remains unprofitable with no revenue expected in the near term. Cash burn risks threaten funding beyond mid-2027.
The market is correcting with no clear consensus revenue growth or fair value. Our view differs by focusing on the risk of continued losses and cash burn despite management's funding runway claims.
Breaks if: cash falls below level needed to fund operations into second half of 2027
Maintain sufficient cash, cash equivalents, and marketable securities to fund operations through the second half of 2027.
Stated as a priority in 2 of last 2 quarters. Management expects current cash, cash equivalents, and marketable securities to fund operations into the second half of 2027. Financials show negative cash from operations of -$54.5M in 2025-Q1 and -$89.8M in 2026-Q1, indicating ongoing cash burn. The trajectory is consistent with management's stated funding runway.
“Eikon expects its current cash, cash equivalents, and marketable securities, to fund operations into the second half of 2027.”
“Eikon expects its current cash, cash equivalents, and marketable securities, which includes proceeds from its February 2026 IPO, will fund operations into the second half of 2027.”
Breaks if: net income losses worsen beyond -$82.9M next quarter
Control operating losses and cash burn to sustain operations during development phase.
Stated as a priority in 2 of last 2 quarters. Operating income worsened from -$71.4M in 2025-Q1 to -$87.3M in 2026-Q1, and net income declined from -$68.2M to -$82.9M over the same period. Cash from operations also declined, indicating increasing cash burn. The trajectory shows ongoing investment with increasing losses, consistent with management's focus on managing operating losses.
“Operating income was -$87.3M and net income was -$82.9M in 2026-Q1.”
“Operating income was -$71.4M and net income was -$68.2M in 2025-Q1.”
Breaks if: operating losses worsen beyond -$87.3M next quarter
Control operating losses and cash burn to sustain operations during development phase.
Stated as a priority in 2 of last 2 quarters. Operating income worsened from -$71.4M in 2025-Q1 to -$87.3M in 2026-Q1, and net income declined from -$68.2M to -$82.9M over the same period. Cash from operations also declined, indicating increasing cash burn. The trajectory shows ongoing investment with increasing losses, consistent with management's focus on managing operating losses.
“Operating income was -$87.3M and net income was -$82.9M in 2026-Q1.”
“Operating income was -$71.4M and net income was -$68.2M in 2025-Q1.”
Breaks if: lack of clinical progress or negative trial results
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
